Atlas Trials

Studying the Safety and Determining the Optimal Dose of Novobiocin in Patients With Tumors That Have Alterations in DNA Repair Genes

Clinical trial NCT05687110 · RECRUITING

Trial details

NCT number
NCT05687110
Sponsor
National Cancer Institute (NCI)
Status
RECRUITING
Phase
Phase 1
Study type
INTERVENTIONAL
Metastatic Malignant Solid NeoplasmUnresectable Malignant Solid Neoplasm
Start date
2023-07-06
Primary completion
2028-07-01
Enrollment
43

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.